Diagnosis and Treatment of CAD in Severe PAD After Lower Extremity Revascularization
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Aurora, Cleveland, Dallas, Gainesville, Nashville, Pittsburgh, and Seattle, United StatesSee the 7 sites
- Trial code
- Status
- Withdrawn
- Started
- 1 Nov 2024
- Ended
- 1 Nov 2024
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Coronary computed topography (CT) angiography with FFR-CT
- Record updated
- 26 September 2025
- Why it stopped
- Intent to fund was rescinded
Who can take part
- Age
- 50 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Male or female 50 to 85
- Severe intermittent claudication with ABI < 0.6 or monophasic waveform if non-compressible and TBI < 0.6
- Chronic limb threatening ischemia (CLTI) with pain at rest (Rutherford Category 4) with ABI < 0.5 or TBI < 0.6
- CLTI with minor tissue loss (Rutherford Category 5) with ABI < 0.5 or TBI < 0.6
- Completed Lower Extremity Revascularization and enrolled within 45 days
- The patient or legal representative will provide informed written consent
- The patient has a life expectancy of at least 1 year
Who cannot take part
- Prior coronary artery bypass graft (CABG) revascularization surgery
- Prior percutaneous coronary intervention (PCI) with angioplasty or stenting
- Pregnancy, Human Immunodeficiency Virus, or organ transplant recipients
- Uncompensated congestive heart failure (NYHA class IV)
- Myocardial infarction or stroke within the past 90 days
- Current malignancy or malignancy within the last two years unless the treating oncologic physician provides prognosis of an anticipated 2- year survival (i.e., adequately treated non-melanoma skin cancer or adequately treated prostate cancer without metastatic disease)
- Any condition the review panel determines would make the patient unsuitable for participation in the study
- Congestive heart failure with Ejection Fraction < 30%
- Severe Chronic renal disease (Glomerular Filtration Rate, GFR < 30) or on hemodialysis
- Major tissue loss of the ischemic limb (Rutherford Category 6)
- Presence of a pacemaker
- Elevated liver function tests more than twice the upper limit of normal
Where in United States
- Rocky Mountain Regional VA Medical Center, Aurora, COAurora, United States
- Louis Stokes VA Medical Center, Cleveland, OHCleveland, United States
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TXDallas, United States
- North Florida/South Georgia Veterans Health System, Gainesville, FLGainesville, United States
- Tennessee Valley Healthcare System Nashville Campus, Nashville, TNNashville, United States
- VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PAPittsburgh, United States
- VA Puget Sound Health Care System Seattle Division, Seattle, WASeattle, United States
About the trial
What the trial wants to find out
Peripheral artery disease, lack or blood flow to the legs, has a high prevalence in the Veteran population. In patients with severe peripheral artery disease that requires an endovascular or surgical intervention for lower leg revascularization, the long-term mortality of approximately 50% is worse that most cancers. The goal of this study is to develop a management strategy to improve cardiovascular outcomes in this high-risk peripheral artery disease population after lower extremity revascularization.
The 2 groups in the trial
- Investigational Treatment StrategyTreatment being tested
This arm will have a coronary CTA with FFR-CT with selective coronary artery revascularization plus optimal medical therapy after lower extremity revascularization
Treatment: Coronary computed topography (CT) angiography with FFR-CT
- StandardNo study treatment, for comparison
This arm will have optimal medical therapy after lower extremity revascularization
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Diagnosis and Treatment of Coronary Artery Disease in Severe Peripheral Artery Disease After Lower Extremity Revascularization
- Record updated
- 26 September 2025